Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Bioorg Med Chem. 2013 Jan 9;21(5):1123–1135. doi: 10.1016/j.bmc.2012.12.043

Figure 7.

Figure 7

Determination of anti-proliferative effects exerted on cultures of HASMCs by NO-donors, using an MTT viability assay. (*) Indicates a statistically significant difference (p < 0.05) between the given compound/concentration combination and the vehicle alone. The graphical data represents the mean ± SE of triplicate determinations on the extent of HASMC proliferation inhibition in the presence of a) A6’–A10’ and b) B6’–B10’.